Ten common mistakes in the management of lupus nephritis

American Journal of Kidney Diseases

Volumn 63, Issue 4, 2014, Pages 667-676

  Bose, Bhadran ^a   Silverman, Earl D ^b   Bargman, Joanne M ^a,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Antimalarial agents and nonadherence; azathioprine; cyclophosphamide; lupus nephritis

Indexed keywords

ANTIMALARIAL AGENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

HEMATURIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY BIOPSY; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; PREGNANCY; PROTEINURIA; REVIEW; TREATMENT REFUSAL; URINE SEDIMENT;

ANTIMALARIAL AGENTS AND NONADHERENCE; AZATHIOPRINE; CYCLOPHOSPHAMIDE; LUPUS NEPHRITIS;

ADULT; ANTIMALARIALS; AZATHIOPRINE; BONE DENSITY; CYCLOPHOSPHAMIDE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PATIENT COMPLIANCE; PNEUMOCYSTIS INFECTIONS; PNEUMOCYSTIS JIROVECII; PREGNANCY; PREGNANCY COMPLICATIONS; RENAL DIALYSIS;

EID: 84897110519     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.056     Document Type: Review

References (63)

1. H.M. Bastian, J.M. Roseman, and G. McGwin Jr. et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis Lupus 11 3 2002 152 160
2. M. Petri, S. Perez-Gutthann, J.C. Longenecker, and M. Hochberg Morbidity of systemic lupus erythematosus: role of race and socioeconomic status Am J Med 91 4 1991 345 353
3. B.A. Pons-Estel, L.J. Catoggio, and M.H. Cardiel et al. The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus: ethnic and disease heterogeneity among "Hispanics." Medicine (Baltimore) 83 1 2004 1 17
4. M. Adler, S. Chambers, C. Edwards, G. Neild, and D. Isenberg An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period Rheumatology (Oxford) 45 9 2006 1144 1147
5. M.M. Ward, and S. Studenski Clinical prognostic factors in lupus nephritis. The importance of hypertension and smoking Arch Intern Med 152 10 1992 2082 2088
6. W. Williams, L.A. Sargeant, M. Smikle, R. Smith, H. Edwards, and D. Shah The outcome of lupus nephritis in Jamaican patients Am J Med Sci 334 6 2007 426 430
7. R. Cervera, M.A. Khamashta, and J. Font et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients Medicine (Baltimore) 82 5 2003 299 308
8. A. Zonana-Nacach, P. Yanez, F.J. Jimenez-Balderas, and A. Camargo-Coronel Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus Lupus 16 12 2007 997 1000
9. H.A. Austin III, J.H. Klippel, and J.E. Balow et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs N Engl J Med 314 10 1986 614 619
10. F.A. Houssiau, C. Vasconcelos, and D. D'Cruz et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide Arthritis Rheum 46 8 2002 2121 2131
11. F.A. Houssiau, C. Vasconcelos, and D. D'Cruz et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide Ann Rheum Dis 69 1 2010 61 64
12. T.M. Chan, F.K. Li, and C.S. Tang et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group N Engl J Med 343 16 2000 1156 1162
13. T.M. Chan, K.C. Tse, C.S. Tang, M.Y. Mok, and F.K. Li Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis J Am Soc Nephrol 16 4 2005 1076 1084
14. G.B. Appel, G. Contreras, and M.A. Dooley et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis J Am Soc Nephrol 20 5 2009 1103 1112
15. E.M. Ginzler, M.A. Dooley, and C. Aranow et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis N Engl J Med 353 21 2005 2219 2228
16. L.M. Ong, L.S. Hooi, and T.O. Lim et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis Nephrology (Carlton) 10 5 2005 504 510
17. J.V. Donadio Jr., K.E. Holley, R.H. Ferguson, and D.M. Ilstrup Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide N Engl J Med 299 21 1978 1151 1155
18. D.T. Felson, and J. Anderson Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis N Engl J Med 311 24 1984 1528 1533
19. A. McKinley, E. Park, and D. Spetie et al. Oral cyclophosphamide for lupus glomerulonephritis: An underused therapeutic option Clin J Am Soc Nephrol 4 11 2009 1754 1760
20. Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis Kidney Int Suppl 2 2 2012 139 274
21. B.J. Fessler, G.S. Alarcon, and G. McGwin Jr. et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual Arthritis Rheum 52 5 2005 1473 1480
22. G.S. Alarcon, G. McGwin, and A.M. Bertoli et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) Ann Rheum Dis 66 9 2007 1168 1172
23. G. Ruiz-Irastorza, M.V. Egurbide, and J.I. Pijoan et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus Lupus 15 9 2006 577 583
24. No authors listed. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group N Engl J Med 324 3 1991 150 154
25. E. Tsakonas, L. Joseph, and J.M. Esdaile et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group Lupus 7 2 1998 80 85
26. N. Kasitanon, D.M. Fine, M. Haas, L.S. Magder, and M. Petri Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis Lupus 15 6 2006 366 370
27. A. Siso, M. Ramos-Casals, and A. Bove et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival Lupus 17 4 2008 281 288
28. G.J. Pons-Estel, L.A. Gonzalez, and J. Zhang et al. Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort Rheumatology (Oxford) 48 7 2009 817 822
29. R.A. Levy, V.S. Vilela, and M.J. Cataldo et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study Lupus 10 6 2001 401 404
30. S.J. Lee, E. Silverman, and J.M. Bargman The role of antimalarial agents in the treatment of SLE and lupus nephritis Nat Rev Nephrol 7 12 2011 718 729
31. M.H. Liang, P.H. Schur, and P. Fortin et al. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials Arthritis Rheum 54 2 2006 421 432
32. J.M. Bargman Why are rheumatologists treating lupus nephritis? Nat Clin Pract Nephrol 3 6 2007 296 297
33. Lewis EJ, Schwartz MM, Korbet SM, eds. Membranous lupus glomerulonephritis. In: Lewis EJ SM, Korbet SM, eds. Lupus Nephritis. Oxford: Oxford University Press; 1999:219-240.
34. No authors listed. Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL) Am J Kidney Dis 19 5 1992 473 479
35. G.B. Appel, D.J. Cohen, C.L. Pirani, J.I. Meltzer, and D. Estes Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization Am J Med 83 5 1987 877 885
36. L. Mercadal, S.T. Montcel, and D. Nochy et al. Factors affecting outcome and prognosis in membranous lupus nephropathy Nephrol Dial Transplant 17 10 2002 1771 1778
37. G. Moroni, S. Quaglini, and L. Gravellone et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients Semin Arthritis Rheum 41 5 2012 642 651
38. S. Pasquali, G. Banfi, A. Zucchelli, G. Moroni, C. Ponticelli, and P. Zucchelli Lupus membranous nephropathy: long-term outcome Clin Nephrol 39 4 1993 175 182
39. No authors listed. A controlled study of short-term prednisone treatment in adults with membranous nephropathy N Engl J Med 301 24 1979 1301 1306
40. H.A. Austin III, G.G. Illei, M.J. Braun, and J.E. Balow Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy J Am Soc Nephrol 20 4 2009 901 911
41. J. Radhakrishnan, D.A. Moutzouris, E.M. Ginzler, N. Solomons, Siempos II, and G.B. Appel Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis Kidney Int 77 2 2010 152 160
42. J.T. Swan, D.M. Riche, K.D. Riche, and V. Majithia Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis J Investig Med 59 2 2011 246 258
43. J. Dunbar-Jacob, J.A. Erlen, E.A. Schlenk, C.M. Ryan, S.M. Sereika, and W.M. Doswell Adherence in chronic disease Annu Rev Nurs Res 18 2000 48 90
44. J.J. Caro, M. Salas, J.L. Speckman, G. Raggio, and J.D. Jackson Persistence with treatment for hypertension in actual practice CMAJ 160 1 1999 31 37
45. B.J. Turner, C.J. Newschaffer, D. Zhang, L. Cosler, and W.W. Hauck Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women Med Care 38 9 2000 911 925
46. F. Viller, F. Guillemin, S. Briancon, T. Moum, T. Suurmeijer, and W. van den Heuvel Compliance with drug therapy in rheumatoid arthritis. A longitudinal European study Joint Bone Spine 67 3 2000 178 182
47. T.A. Golper, M.E. Brier, and M. Bunke et al. Risk factors for peritonitis in long-term peritoneal dialysis: The Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies Am J Kidney Dis 28 3 1996 428 436
48. W.F. Keane, F.L. Shapiro, and L. Raij Incidence and type of infections occurring in 445 chronic hemodialysis patients Trans Am Soc Artif Intern Organs 23 1977 41 47
49. N.K. Krane, K. Burjak, M. Archie, and R. O'Donovan Persistent lupus activity in end-stage renal disease Am J Kidney Dis 33 5 1999 872 879
50. C.F. Mojcik, and J.H. Klippel End-stage renal disease and systemic lupus erythematosus Am J Med 101 1 1996 100 107
51. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 2010;69(7):1269-1274.
52. T.P. Van Staa, R.F. Laan, I.P. Barton, S. Cohen, D.M. Reid, and C. Cooper Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy Arthritis Rheum 48 11 2003 3224 3229
53. J.A. Kanis, H. Johansson, and A. Oden et al. A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 6 2004 893 899
54. J.M. Grossman, R. Gordon, and V.K. Ranganath et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Care Res (Hoboken) 62 11 2010 1515 1526
55. J.D. Ringe, A. Dorst, H. Faber, E. Schacht, and V.W. Rahlfs Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis Rheumatol Int 24 2 2004 63 70
56. S.L. Teitelbaum, M.P. Seton, and K.G. Saag Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 63 2 2011 325 328
57. H.N. Bernstein Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy Am J Med 75 1A 1983 25 34
58. M.F. Marmor, R.E. Carr, M. Easterbrook, A.A. Farjo, and W.F. Mieler Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: A report by the American Academy of Ophthalmology Ophthalmology 109 7 2002 1377 1382
59. D.J. Spalton Retinopathy and antimalarial drugs - the British experience Lupus 5 suppl 1 1996 S70 S72
60. B. Godeau, V. Coutant-Perronne, and D. Le Thi Huong et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases J Rheumatol 21 2 1994 246 251
61. E. Catherinot, F. Lanternier, M.E. Bougnoux, M. Lecuit, L.J. Couderc, and O. Lortholary Pneumocystis jirovecii pneumonia Infect Dis Clin North Am 24 1 2010 107 138
62. S. Arends, C. Grootscholten, and R.H. Derksen et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis Ann Rheum Dis 71 6 2012 966 973
63. M. Petri, D. Howard, and J. Repke Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience Arthritis Rheum 34 12 1991 1538 1545